Loading...
Market
What will be the market share of mRESVIA RSV Vaccine in Canada by Nov 8, 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market analysis reports from health industry analysts or official health agency publications
Story
Moderna's mRESVIA RSV Vaccine Approved by Health Canada for Adults 60 and Older
Nov 8, 2024, 03:13 PM
Moderna has received approval from Health Canada for its respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 years and older. This marks the first mRNA-based vaccine for RSV to be authorized in Canada. The approval was announced on Friday, making it a significant milestone for the vaccine maker. The stock ticker for Moderna is $MRNA.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Pfizer's Abrysvo • 25%
Moderna's RSV vaccine • 25%
GSK's RSV vaccine • 25%
Other • 25%
Pfizer leads • 25%
GSK leads • 25%
Moderna leads • 25%
Other leads • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Capvaxive leads • 33%
Prevnar 20 leads • 33%
Equal market share • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%